Department of Hematology, School of Medicine, İstanbul Medipol University, İstanbul, Turkey
Department Transfusion and Apheresis Medicine, School of Medicine, İstanbul Medipol University, İstanbul, Turkey
Turk J Med Sci. 2020 Dec 17;50(8):1781-1785. doi: 10.3906/sag-2009-77.
BACKGROUND/AIM: A SARS-Cov2 infection which was first arised from Wuhan in December 2019 and named as COVID-19. Still there lacks either a specific treatment or a vaccine to treat COVID-19. Convalescent plasma (CP) was previously used successfully to treat SARS-CoV-1 and MERS infections. Health authority in Turkey has published a guideline to integrate this promising option in the treatment process of patients who are prone to high risk of developing severe COVID 19.
Forty consecutive patients who had received CP at our center were included in the study. Demographics, COVID-19 specific parameters, biomarkers to detect the severity of COVID-19 infection and outcome variables were collected retrospectively. The correlation between outcome variables and the independent predictors of the outcome were reported.
Median age of the patients was 57.5 and 72.5% were male. At least one COVID-19 PCR test was confirmed to be positive in 75% of patients. Remaining 25% had a Chest-CT which was reported to be compatible with an ongoing COVID-19. All patients (100%) were classified as having severe COVID-19 infection. Over a half of the patients harbored an oxygen saturation of less than 90 despite of a continuous 5 L/min support of O2. 82.5% of the patients had a need for mechanical ventilation and 45.5% had a need for invasive mechanical ventilation. Nine out of 10 patients who have received CP outside ICU have totally recovered from COVID-19 at a median of 9 days, and a half of the patients who needed invasive mechanical ventilation were successfully free of mechanical ventilation support and managed to recover from COVID-19.
According to the results of this study, CP is an efficient conjunct to conventional therapy against COVID-19 with a favorable safety profile.
背景/目的：一种由 2019 年 12 月在中国武汉首次出现的 SARS-CoV2 感染，被命名为 COVID-19。目前还没有专门用于治疗 COVID-19 的药物或疫苗。恢复期血浆（CP）之前已成功用于治疗 SARS-CoV-1 和 MERS 感染。土耳其卫生当局发布了一项指南，将这一有前途的治疗方案纳入治疗易发生严重 COVID-19 风险的患者的治疗过程中。
本研究纳入了在我们中心接受 CP 治疗的 40 例连续患者。回顾性收集患者的人口统计学、COVID-19 特异性参数、用于检测 COVID-19 感染严重程度的生物标志物和结局变量。报告了结局变量与结局的独立预测因素之间的相关性。
患者的中位年龄为 57.5 岁，72.5%为男性。75%的患者至少有一次 COVID-19 PCR 检测结果为阳性。其余 25%的患者有胸部 CT，报告与正在进行的 COVID-19 相符。所有患者（100%）均被归类为患有严重 COVID-19 感染。尽管持续给予 5 L/min 的氧气支持，但超过一半的患者的血氧饱和度仍低于 90%。82.5%的患者需要机械通气，45.5%的患者需要有创机械通气。在 ICU 外接受 CP 的 10 名患者中有 9 名患者在中位数为 9 天的时间内完全从 COVID-19 中康复，需要有创机械通气的患者中有一半成功地停止了机械通气支持并从 COVID-19 中康复。
根据这项研究的结果，CP 是一种对抗 COVID-19 的有效联合治疗方法，具有良好的安全性。
